Veru announces positive updated data from phase 1b/2 sabizabulin study in men with metastatic castration resistant prostate cancer at the 2021 esmo congress

Miami, sept. 20, 2021 (globe newswire) -- veru inc. (nasdaq: veru), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, today announced that updated clinical data from the positive phase 1b/2 study of sabizabulin (veru-111) in 80 men with metastatic castration resistant prostate cancer who have progressed on at least one novel androgen receptor targeting agent were presented at the european society for medical oncology (esmo) congress 2021 being held september 16-21, 2021. sabizabulin is a new oral chemical entity that represents a novel class of agents that target unique binding sites on microtubules to disrupt both the cytoskeleton and androgen receptor transport.
VERU Ratings Summary
VERU Quant Ranking